AbbVie Inc. $ABBV Shares Purchased by VCI Wealth Management LLC

VCI Wealth Management LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 36.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 12,506 shares of the company’s stock after acquiring an additional 3,370 shares during the quarter. VCI Wealth Management LLC’s holdings in AbbVie were worth $3,271,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ABBV. Verus Financial Partners Inc. raised its position in shares of AbbVie by 1.7% in the 3rd quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after acquiring an additional 35 shares during the period. Lifelong Wealth Advisors Inc. grew its holdings in AbbVie by 2.1% during the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock valued at $459,000 after purchasing an additional 36 shares during the period. IMG Wealth Management Inc. grew its holdings in AbbVie by 22.8% during the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock valued at $51,000 after purchasing an additional 36 shares during the period. Foundry Financial Group Inc. grew its holdings in AbbVie by 4.6% during the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after purchasing an additional 37 shares during the period. Finally, DecisionMap Wealth Management LLC increased its stake in AbbVie by 3.2% in the third quarter. DecisionMap Wealth Management LLC now owns 1,207 shares of the company’s stock valued at $316,000 after purchasing an additional 37 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Down 2.1%

NYSE:ABBV opened at $288.66 on Tuesday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $298.74. The firm has a market capitalization of $509.99 billion, a price-to-earnings ratio of 49.68, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24. The stock’s 50 day moving average price is $269.81 and its two-hundred day moving average price is $237.57.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the prior year, the firm posted $1.86 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is currently 119.10%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals announced a global license agreement to advance next-generation migraine treatments, potentially worth up to $757 million. The deal adds another growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
• Positive Sentiment: Positive migraine data: A Phase 3 study published in The Lancet Neurology reportedly delivered a favorable result, supporting the commercial potential of AbbVie’s migraine portfolio. AbbVie Lands Phase 3 Migraine Study Win
• Positive Sentiment: Analyst optimism increased: Cantor Fitzgerald raised its price target to $325, while RBC, Canaccord Genuity, Leerink Partners and Morgan Stanley lifted targets to $330, $338, $342 and $346, respectively. The revisions reflect confidence in AbbVie’s immunology transition and raised outlook. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: Strong operating performance: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products are offsetting Humira’s decline, and management raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
• Positive Sentiment: Dividend increase: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, signaling confidence in cash flow and reinforcing the stock’s income appeal.
• Neutral Sentiment: Legal win: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug-price controls, potentially reducing near-term regulatory uncertainty. AbbVie Wins Drug Price Control Lawsuit
• Negative Sentiment: Transition and valuation risks remain: Humira sales continue to decline, leaving investors dependent on Skyrizi, Rinvoq and pipeline launches to sustain growth. After a sharp rally, ABBV’s elevated valuation and proximity to its 52-week high may also be prompting profit-taking despite the positive updates. AbbVie’s Humira Era Is Fading

Wall Street Analyst Weigh In

Several research firms have weighed in on ABBV. Barclays increased their target price on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a report on Wednesday, October 21st. BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Wells Fargo & Company lifted their price target on shares of AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $294.67.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.